In addition to being the director of strategic planning at Quintiles you are also the Chairman of BioSingapore. In this context, can you please introduce BioSingapore…
In Conversation
Would you begin by giving an introduction to our international readers of the institute, highlighting recent milestones & achievements and the current focus areas of its…
For those that are not familiar with your name, would you start by introducing yourself? After obtaining my PhD in cardiovascular physiology I moved to Boston…
Rare Voices Australia is a new organisation that has been established after the national rare diseases symposium in 2011. Can you please begin with giving our…
Among Big Pharma, Sanofi has a track record of placing a lot of faith in emerging markets – with local production, a large product portfolio, and…
Can you give us a historical overview of the main milestones and achievements of Ottobock since it settled in Mexico in 1995? Ottobock was founded in…
Can you give us a historical overview of the company and tell us about the vision behind its creation? Vitalmex is a very humanistic company that…
IMSS is a central pillar in the Mexican healthcare system, covering all Mexicans working for the declared formal private sector. How do you assess the quality…
You noted that, in the ‘old days’, the pharma business had the following characteristics: first of all, it was a molecule-driven business, fueled by blockbuster medicines…
Dr. McLoughlin, you were appointed to your post in April of this year. Can you please give us an impression of what you inherited at this…
PwC has been the advocate of convergence in the industry for a very long time, what does that mean and what are the implications for the…
You worked several years ago in Mexico, and there have been significant changes in the country since then. From your perspective, how did the Mexican pharmaceutical…
